PER-077-00已完成未知
A DOUBLE-BLIND, RANDOMLY CONTROLLED PLACEBO STUDY TO EVALUATE THE RENAL PROTECTIVE EFFECTS OF LOSARTAN IN PATIENTS WITH DIABETES MELLITUS NON-INSULIN DEPENDENTS AND NEPHROPATHY
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2000年9月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
入排标准
入选标准
- •- Diabetes diagnosed after the age of 30
- •- Insulin not required within 6 months of first being diagnosed with Non-insulin
- •Dependent Diabetes Mellitus
- •- No history of diabetic ketoacidosis
- •- Patients may be currently treated with diet, oral hypoglycemics or insulin
- •- Patients must have proteinuria defined as: Urine protein >1+ on dipstick at the
- •initial screening visit
- •- Patients with hypertension (high blood pressure) must have a sitting blood pressure
- •>200/110 mm Hg at Visit 1
排除标准
- •- Patients with insulin-dependent diabetes mellitus (juvenile onset)
- •- Patients treated with an ACE inhibitor or angiotensin II antagonist (AIIA) for >5
- •- Patients treated with ACE inhibitor or AIIA therapy for 5 years or less may enter the
- •study provided therapy is discontinued during the 6 week screening period prior to
- •randomization
- •- History of myocardial infarction (MI) (heart attack) or coronary artery bypass graft
- •(CABG) surgery within the past 1 month
- •- History of cerebral vascular accident (CVA) (stroke) or percutaneous transluminal
- •coronary angioplasty (PTCA) within the past 6 months
- •- History of transient ischemic attacks (TIA) within the past year. Patients with
- •unstable angina are excluded until stabilized
- •- Heart failure requiring ACE inhibitor therapy
- •- Steroids (oral or parenteral) or immunosuppressives are not permitted. Debilitating
- •psychological illness
- •- Evidence of significant hepatic (liver) dysfunction: History of allergy to losartan
- •- Known positive test for HIV or patients known to be hepatitis B or C antigen carriers
- •- Pregnant or nursing women
- •- Females of childbearing age must either be surgically sterilized or, if sexually
- •active, using an effective form of contraception and may enter only if an
- •exclusionary pregnancy test is done within approximately 72 hours prior to
- •randomization
- •- Pregnancy tests will be done every 3 months during the study and at the time of
- •discontinuation
研究者
相似试验
进行中(未招募)
不适用
A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S)COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITHETANERCEPT PLUS DMARD(S)Rheumatoid ArthritisEUCTR2011-005448-87-HUPfizer Inc, 235 East 42nd Street, New York, NY 10017320
进行中(未招募)
不适用
A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S)COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITHETANERCEPT PLUS DMARD(S)MedDRA version: 16.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2011-005448-87-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017320
已完成
2 期
A STUDY TO EVALUATE THE EFFICACY OF DIFFERENT DOSES OF CHANNA STRIATUS EXTRACT AMONG PRIMARY KNEE OSTEOARTHRITIS PATIENTSPrimary Knee OsteoarthritisarthritisosteoarthritisTCTR20170513004niversiti Sains Malaysia120
已完成
不适用
PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF AERUCIN® ASADJUNCT THERAPY TO ANTIBIOTICS IN THE TREATMENT OF P. AERUGINOSAPNEUMONIA-J151 Pneumonia due to PseudomonasPneumonia due to PseudomonasJ151PER-019-18Aridis Pharmaceuticals, Inc,
进行中(未招募)
1 期
To study the effectiveness and safety of REN001 in PMM patients after 24 weeks of treatmentPrimary Mitochondrial MyopathyMedDRA version: 20.0Level: PTClassification code 10027710Term: Mitochondrial myopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-002855-40-ITReneo Pharma LTD200
